Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cell-based therapies developer MaxCyte said it had signed a commercial license agreement with genome editing company Editas Medicine.
Editas Medicine would use MaxCyte's Flow Electroporation technology and ExPERT instruments for the advancement of engineered cell medicines.
These medicines would include EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia.
Editas Medicine would obtain non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop up to five therapies including four immuno-oncology therapies.
In return, MaxCyte would receive development and approval milestones and sales-based payments in addition to other licensing fees.